UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2005
IMMTECH INTERNATIONAL, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 8733 39-1523370
--------------------------------------------------------------------------------
(State or Other (Commission File Number) (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation)
150 Fairway Drive, Suite 150, Vernon Hills, Illinois 60061
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (847) 573-0033
Not Applicable
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
-------------
Immtech International, Inc. ("Immtech") received on April 25, 2005
an advance payment of $1.0 million, aggregating to approximately $4.023 million
to date, for the advancement of clinical trials of DB289 in the treatment of
malaria. The funds were received from the Medicines For Malaria Venture, a
foundation established in Switzerland ("MMV"), pursuant to a Testing Agreement
dated November 26, 2003 among Immtech, MMV and The University of North
Carolina at Chapel Hill (the "MMV Agreement").
In addition to the $1 million payment, MMV previously advanced to
Immtech $668,000 in fiscal 2004 and approximately $2.3 million in fiscal 2005,
to fund development and commercialization efforts of Immtech's first oral drug
candidate, DB289, for treatment of malaria. Each funding advance is contingent
upon Immtech's successful attainment of milestones set forth in the MMV
Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
IMMTECH INTERNATIONAL, INC.
Date April 26, 2005 By: /s/ T. Stephen Thompson
-----------------------------------
T. Stephen Thompson
Chief Executive Officer and
President